Restarting Wegovy After a 4-Month Break: A Practical Guide

Step 1: understand why retitration is not optional at this stage

Four months is long enough for the body to lose most of the tolerance built up during the original course. Semaglutide slows gastric emptying and suppresses appetite through GLP-1 receptor activity, and that activity needs to be reintroduced gradually to give the gut time to readjust. Jumping back to, say, 1.7 mg or 2.4 mg after a gap of this length significantly increases the risk of severe nausea, vomiting and diarrhoea, the side effects that cause many people to abandon treatment entirely. Starting lower reduces that risk substantially. The NHS patient guidance on semaglutide is clear that dosing is always managed by the prescriber and adjusted based on how you are tolerating the medicine, not on what you previously reached.

This is a question our prescribers hear most weeks from patients who have had a supply gap, a change in circumstances or a planned treatment pause. The honest answer is always the same: the restart dose matters, and no one should self-prescribe a return to their previous level.

In practical terms, retitration from 0.25 mg typically means four weeks at that level before any increase is considered, the same process as starting for the first time. Depending on tolerability, the path to 2.4 mg can take four to six months. That is a genuine commitment, worth thinking through before restarting.

Step 2: get a clinical assessment before ordering anything

Wegovy is a prescription-only medicine. Returning to it after four months requires a fresh prescriber review, not just a repeat of an old prescription. A good assessment covers your current weight, any changes to your health since you stopped, any new medicines you are taking (some interact with semaglutide), and whether the original reason for pausing affects which dose is appropriate now.

It is also worth knowing that the NICE recommendation for semaglutide (TA875) specifies use within a specialist weight management service for a maximum of two years; private prescribing sits outside that pathway, but a responsible private prescriber still applies the same clinical logic. That means checking whether your BMI and weight-related conditions still meet the licensed criteria, and whether your goals and expectations are realistic given the retitration timeline.

If you were previously treated elsewhere and want to transfer your care, you will need to provide evidence of your treatment history and current dose. At nume, every returning or transferring patient goes through the same same-day clinical review by a GPhC-registered Independent Prescriber as any new patient, no shortcuts, no assumptions based on prior use.

Step 3: plan for the side effects that tend to come back

People who restart GLP-1 medicines after a significant break often find the early side effects return almost as strongly as they did the first time. Nausea is the most reported. So are loose stools, indigestion and a general feeling of fatigue in the first days after each dose step up. These typically settle within one to two weeks at each level, as they did originally, but they can feel discouraging when you had previously moved past them.

Keeping portions small, eating slowly and staying well hydrated all help. Fatty or heavily spiced food is harder to tolerate during titration. The Patient Information Leaflet that comes with your pens covers practical management in detail, and that is always the reference point for side effect questions, not anecdotal advice online.

Certain symptoms warrant prompt medical attention regardless of when they occur in your treatment: severe stomach pain that spreads toward the back, persistent vomiting that prevents you keeping fluids down, or signs of an allergic reaction. The MHRA's Yellow Card scheme lets you report any suspected side effect directly, and doing so helps build the safety picture for everyone on these medicines.

Step 4: think through cost and continuity before you restart

Restarting after a four-month gap often means restarting at the lower-priced doses, but the titration period means you will be paying for several dose steps before reaching your maintenance dose again. Worth factoring in before you begin. Our Wegovy pricing page sets out what current private treatment costs across the dose range, so you can plan ahead.

Continuity of supply also matters more than people realise. One of the more common reasons for gaps in treatment is availability, and Wegovy has experienced supply pressures across the UK market. Before restarting, it is sensible to confirm that your pharmacy has a reliable supply chain for the doses you will need across the full retitration period. Our pharmacy sources medicines through the licensed UK supply chain, with Novo Nordisk authorised supplier relationships, and every order is reviewed before dispatch.

If you stopped after only a month or two rather than four, the retitration pathway can sometimes be shorter, the considerations after a two-month break differ in meaningful ways. And if your gap has been closer to six months, a prescriber may treat the restart more conservatively still; you can read more about what to expect after a six-month pause. For a broader grounding in how semaglutide works and what the clinical evidence shows, the Wegovy overview covers the full picture.

It is also worth knowing that shorter gaps carry their own nuances: if your break was around one month, you can find out how restarting after one month typically works, and if you paused for closer to three months, the guidance on restarting wegovy after three months explains how prescribers approach that specific window.

If you are ready to restart, the right first step is a clinical consultation rather than an order. Check your eligibility with our prescribers and get a plan built around where you are now, not where you left off.